Scan to Download ios&Android APP

Trade ENDRA Life Sciences Inc. - NDRA CFD

-
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
Day's Range* N/A
1-Year Change* N/A
Volume N/A
Average Vol. (3m) 17.3905
52 wk Range N/A
Market Cap 23.0524
P/E Ratio N/A
Shares Outstanding 63174500
Revenue N/A
EPS -0.28001
Dividend (Yield %) N/A
Beta 1.34247
Next Earnings Date Aug 15, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

ENDRA Life Sciences Inc. Events

Time (UTC) Country Event
Wednesday, August 10, 2022
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0.51558 0.35162 0.00617 0 0 0
Revenue 0.51558 0.35162 0.00617 0
Cost of Revenue, Total 0.23588 0.17278 0 0
Gross Profit 0.2797 0.17884 0.00617 0
Total Operating Expense 2.30734 4.97768 9.02518 10.8436 11.5019 11.1897
Selling/General/Admin. Expenses, Total 1.57609 2.87382 4.01518 4.26859 5.58397 6.01577
Research & Development 0.49538 1.93108 4.72247 6.575 5.91794 5.48253
Operating Income -1.79176 -4.62606 -9.01901 -10.8436 -11.5019 -11.1897
Other, Net -0.98361 -0.7509 -0.77725 -0.1069 0.00884 -0.04155
Net Income Before Taxes -2.77537 -5.37696 -9.79626 -13.306 -11.7255 -11.2312
Net Income After Taxes -2.77537 -5.37696 -9.79626 -13.306 -11.7255 -11.2312
Net Income Before Extra. Items -2.77537 -5.37696 -9.79626 -13.306 -11.7255 -11.2312
Net Income -2.77537 -5.37696 -9.79626 -13.306 -11.7255 -11.2312
Income Available to Common Excl. Extra. Items -2.77537 -5.37696 -9.79626 -17.5257 -12.121 -11.3523
Income Available to Common Incl. Extra. Items -2.77537 -5.37696 -9.79626 -17.5257 -12.121 -11.3523
Dilution Adjustment 0
Diluted Net Income -2.77537 -5.37696 -9.79626 -17.5257 -12.121 -11.3523
Diluted Weighted Average Shares 3.64027 2.75696 4.50487 7.49998 19.1922 40.9227
Diluted EPS Excluding Extraordinary Items -0.76241 -1.95033 -2.17459 -2.33677 -0.63156 -0.27741
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.76241 -1.95033 -2.11076 -2.33677 -0.63156 -0.28495
Unusual Expense (Income) 0.28754 0 -0.3086
Interest Income (Expense), Net Non-Operating -2.35547 -0.23243 0
Total Adjustments to Net Income -4.21978 -0.39555 -0.12107
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 2.26724 3.20019 2.65074 3.07154 2.85527
Selling/General/Admin. Expenses, Total 1.43435 1.45527 1.47742 1.64874 1.64225
Research & Development 1.14149 1.74493 1.17332 1.4228 1.21302
Unusual Expense (Income) -0.3086 0 0 0 0
Operating Income -2.26724 -3.20019 -2.65074 -3.07154 -2.85527
Interest Income (Expense), Net Non-Operating 0 0 0 0
Other, Net -0.00204 0.00109 -0.00751 -0.03309 -0.00293
Net Income Before Taxes -2.26928 -3.1991 -2.65824 -3.10463 -2.8582
Net Income After Taxes -2.26928 -3.1991 -2.65824 -3.10463 -2.8582
Net Income Before Extra. Items -2.26928 -3.1991 -2.65824 -3.10463 -2.8582
Net Income -2.26928 -3.1991 -2.65824 -3.10463 -2.8582
Total Adjustments to Net Income -0.12107 0 0 0 0
Income Available to Common Excl. Extra. Items -2.39035 -3.1991 -2.65824 -3.10463 -2.8582
Income Available to Common Incl. Extra. Items -2.39035 -3.1991 -2.65824 -3.10463 -2.8582
Diluted Net Income -2.39035 -3.1991 -2.65824 -3.10463 -2.8582
Diluted Weighted Average Shares 37.7725 41.6757 41.9125 42.2751 43.0542
Diluted EPS Excluding Extraordinary Items -0.06328 -0.07676 -0.06342 -0.07344 -0.06639
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.07145 -0.07676 -0.06342 -0.07344 -0.06639
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 0.19559 5.88215 6.94956 6.5351 8.20774 12.0941
Cash and Short Term Investments 0.14495 5.60188 6.47138 6.17421 7.22732 9.46153
Cash 0.14495 5.60188 6.47138 6.17421 7.22732 9.46153
Total Inventory 0.04011 0.19168 0.05944 0.11344 0.58962 1.28458
Other Current Assets, Total 0.01054 0.01425 0.27332 0.1307
Total Assets 0.49076 6.1237 7.22279 7.17627 8.76498 12.8746
Property/Plant/Equipment, Total - Net 0.29517 0.24155 0.27323 0.64117 0.55125 0.77454
Property/Plant/Equipment, Total - Gross 0.57132 0.57918 0.67918 1.0841 1.13712 1.35634
Accumulated Depreciation, Total -0.27615 -0.33763 -0.40595 -0.44293 -0.58587 -0.5818
Total Current Liabilities 1.38453 0.84821 0.97458 2.07279 0.98666 1.54377
Accounts Payable 0.22774 0.78026 0.63147 1.27843 0.40291 0.79105
Payable/Accrued 0 0.05031
Accrued Expenses 0.20681 0.06795 0.2928 0.49629 0.58375 0.75272
Notes Payable/Short Term Debt 0.94998 0 0 0.29807 0 0
Total Liabilities 1.38453 0.84821 0.97458 2.4156 1.59566 2.0904
Total Long Term Debt 0 0 0 0 0.33708 0.02848
Total Equity -0.89377 5.27549 6.24821 4.76067 7.16932 10.7843
Common Stock 0.00025 0.00039 0.00074 0.00084 0.0034 0.00425
Additional Paid-In Capital 11.5435 23.1705 33.9392 49.9337 64.4936 79.4569
Retained Earnings (Accumulated Deficit) -12.5185 -17.8954 -27.6917 -45.2174 -57.3385 -68.6908
Other Equity, Total 0.081 0 0.04353 0.01079 0.01386
Total Liabilities & Shareholders’ Equity 0.49076 6.1237 7.22279 7.17627 8.76498 12.8746
Total Common Shares Outstanding 3.64027 3.92303 7.42264 8.4214 34.0497 42.5545
Total Receivables, Net 0.00685 0
Accounts Receivable - Trade, Net 0.00685 0
Prepaid Expenses 0.0675 0.14542 0.11675 0.3908 1.348
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Other Liabilities, Total 0.34281 0.27191 0.51815
Total Preferred Shares Outstanding 0.00634 0.00014 0.00014
Other Long Term Assets, Total 0.00599 0.00599
Long Term Debt 0.33708 0.02848
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 18.3514 16.343 14.4701 12.0941 10.119
Cash and Short Term Investments 16.8428 14.0433 11.7932 9.46153 7.12736
Cash 16.8428 14.0433 11.7932 9.46153 7.12736
Total Inventory 0.72661 1.32479 1.49974 1.28458 1.93026
Prepaid Expenses 0.77609 0.96892 1.1772 1.348 1.06141
Other Current Assets, Total 0.00599 0.00599
Total Assets 18.8988 17.2426 15.3142 12.8746 10.9367
Property/Plant/Equipment, Total - Net 0.54738 0.89959 0.83809 0.77454 0.81168
Property/Plant/Equipment, Total - Gross 1.16467 1.55061 1.51893 1.35634 1.41252
Accumulated Depreciation, Total -0.61729 -0.65102 -0.68085 -0.5818 -0.60084
Total Current Liabilities 0.76583 1.63806 1.57683 1.54377 1.35796
Accounts Payable 0.44795 0.80711 0.74776 0.79105 0.83386
Accrued Expenses 0.31788 0.83095 0.82906 0.75272 0.5241
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 1.04665 2.25274 2.15814 2.0904 1.86806
Total Long Term Debt 0.02848 0.02848 0.02848 0.02848 0.02848
Long Term Debt 0.02848 0.02848 0.02848 0.02848 0.02848
Other Liabilities, Total 0.25235 0.58619 0.55283 0.51815 0.48162
Total Equity 17.8522 14.9899 13.1561 10.7843 9.06863
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.00416 0.00419 0.00422 0.00425 0.00445
Additional Paid-In Capital 77.461 77.8388 78.6954 79.4569 80.6044
Retained Earnings (Accumulated Deficit) -59.7288 -62.9279 -65.5862 -68.6908 -71.549
Other Equity, Total 0.11584 0.07491 0.04267 0.01386 0.00877
Total Liabilities & Shareholders’ Equity 18.8988 17.2426 15.3142 12.8746 10.9367
Total Common Shares Outstanding 41.6147 41.8573 42.1657 42.5545 44.5594
Total Preferred Shares Outstanding 0.00014 0.00014 0.00014 0.00014 0.00014
Other Long Term Assets, Total 0.00599 0.00599 0.00599
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -2.77537 -5.37696 -9.79626 -13.306 -11.7255 -11.2312
Cash From Operating Activities -1.31562 -3.30091 -7.70248 -8.58885 -10.7466 -11.1224
Cash From Operating Activities 0.06494 0.06148 0.06832 0.08058 0.09934 0.11624
Non-Cash Items 1.13983 1.71591 2.38454 4.03871 2.40069 1.24415
Cash Taxes Paid 0 0 0 0 0 0
Cash Interest Paid 0 0 0.04009 0 0.00192 0.05766
Changes in Working Capital 0.25498 0.29866 -0.35908 0.59783 -1.52112 -1.25152
Cash From Investing Activities 0 -0.00786 -0.1 -0.0436 -0.07533 -0.045
Capital Expenditures 0 -0.00786 -0.1 -0.0436 -0.07533 -0.045
Cash From Financing Activities 1.44145 8.7657 8.67198 8.33528 11.875 13.4016
Issuance (Retirement) of Stock, Net 0.005 8.5907 7.73668 5.84478 11.5379 13.4016
Issuance (Retirement) of Debt, Net 1.43645 0.175 0.9353 2.4905 0.33708 0
Net Change in Cash 0.12583 5.45692 0.8695 -0.29717 1.05311 2.23422
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -2.26928 -5.46838 -8.12662 -11.2312 -2.8582
Cash From Operating Activities -2.92348 -5.7229 -8.46965 -11.1224 -3.09887
Cash From Operating Activities 0.03143 0.06515 0.09498 0.11624 0.01904
Non-Cash Items 0.07705 0.44052 0.8 1.24415 0.32172
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0 0 0.04089 0.05766 0
Changes in Working Capital -0.76268 -0.76019 -1.23801 -1.25152 -0.58142
Cash From Investing Activities -0.045 -0.045 -0.045 -0.045 -0.08935
Capital Expenditures -0.045 -0.045 -0.045 -0.045 -0.08935
Cash From Financing Activities 12.5839 12.5839 13.0805 13.4016 0.85405
Issuance (Retirement) of Stock, Net 12.5839 12.5839 13.0805 13.4016 0.85405
Net Change in Cash 9.61544 6.81603 4.56587 2.23422 -2.33417
Issuance (Retirement) of Debt, Net 0 0 0

Still looking for a broker you can trust?

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

ENDRA Life Sciences Inc. Company profile

About ENDRA Life Sciences Inc

ENDRA Life Sciences Inc. is engaged in commercialization of an ultrasound technology for the pre-clinical research market. The Company’s Nexus 128 system, which combines light-based thermoacoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis. The TAEUS platform has capabilities and potential clinical applications, such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature, in real time; enabling ultrasound to view blood vessels from any angle, using only a saline solution contrasting agent, and enabling ultrasound to image blood flow at the capillary level in a region, organ or tissue.

Financial summary

BRIEF: For the nine months ended 30 September 2021, ENDRA Life Sciences Inc revenues was not reported. Net loss applicable to common stockholders decreased 16% to $8.2M. Lower net loss reflects Research and development decrease of 15% to $4.1M (expense), Selling/General/Admin. Expense decrease of 10% to $3.7M (expense), Amortization of debt discount decrease from $232K (expense) to $0K.

Industry: Biotechnology & Medical Research (NEC)

3600 Green Ct Ste 350
ANN ARBOR
MICHIGAN 48105-2440
US

Income statement

People Also Watch

Bitcoin to US Dollar

23,626.30 Price
+2.150% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 66.00

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading